Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 17Lymphoma, B-Cell 17Lymphoma, Large B-Cell, Diffuse 16Lymphoma, Non-Hodgkin 12Recurrence 11Burkitt Lymphoma 10Multiple Myeloma 7Lymphoma 7Neoplasms 6Leukemia, Myeloid, Acute 6Lymphoma, Mantle-Cell 5Leukemia 5Pancreatic Neoplasms 4Lymphoma, Follicular 4Leukemia, Lymphocytic, Chronic, B-Cell 4Hematologic Neoplasms 4Carcinoma, Hepatocellular 4Neoplasm, Residual 3Nasopharyngeal Carcinoma 3Leukemia, B-Cell 3Glioma 3Colorectal Neoplasms 3Breast Neoplasms 3Stomach Neoplasms 2Simpson-Golabi-Behmel syndrome 2Sarcoma, Ewing 2Rhabdomyosarcoma 2Osteosarcoma 2Melanoma 2Lymphoma, B-Cell, Marginal Zone 2

Interventions

Lenalidomide 3Dexamethasone 3ixazomib 2dexamethasone acetate 2dexamethasone 21-phosphate 2auricularum 2Radiotherapy 2Calcium Dobesilate 2pomalidomide 1daratumumab 1cc-486 1Thalidomide 1Sodium Selenite 1Radiation 1Peripheral Blood Stem Cell Transplantation 1Panobinostat 1Melphalan 1Immunotherapy, Adoptive 1Gemcitabine 1Drug Combinations 1Busulfan 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Plasmacytoma × Immunotherapy, Adoptive × Clear all
NCT06429150 2026-04-24

Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma

Shenzhen Geno-Immune Medical Institute

Phase 1/2 Recruiting
20 enrolled
Plasma cell

Multiple Myeloma, Plasmacytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡